KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Short-term Investments (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Short-term Investments for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 14.07% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 14.07% decrease, with the full-year FY2025 number at $1.0 billion, down 14.07% from a year prior.
  • Short-term Investments was $1.0 billion for Q4 2025 at Bio-Rad Laboratories, down from $1.0 billion in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.4 billion in Q1 2023 to a low of $5.6 million in Q2 2021.
  • A 5-year average of $499.6 million and a median of $5.6 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: skyrocketed 24296.71% in 2022, then plummeted 99.59% in 2023.
  • Bio-Rad Laboratories' Short-term Investments stood at $5.6 million in 2021, then surged by 24296.71% to $1.4 billion in 2022, then tumbled by 99.59% to $5.6 million in 2023, then surged by 20907.14% to $1.2 billion in 2024, then decreased by 14.07% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Short-term Investments are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).